Investor Overview

Webcast ImageWebcast
Q3 2014 AtriCure, Inc. Earnings Conference Call (Live)
10/30/14 at 4:30 p.m. ET

Corporate Profile

AtriCure was formed by a team with extensive experience in the medical device industry. The company is focused on developing innovative products using proprietary technology that provides doctors alternative, expedient methods to ablate tissue during surgical procedures.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$15.26 + 0.010.07%54,729
Previous CloseToday's OpenIntraday HighIntraday Low
$15.25$15.29$15.54$15.15
Exchange: NASDAQ (US Dollar)
10/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
07/31/14
Download Documentation Investor Presentation
07/24/14
Download Documentation Q2 Earnings Call Transcript
04/11/14
Download Documentation 2013 Annual Report

All Recent News

DateTitle 
10/09/14AtriCure Completes Enrollment in Post Approval Study for the Synergy™ Ablation System
This is the largest study of its kind to evaluate surgical ablation for the treatment of chronic Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced enrollment in the ABLATE Post Approval Study (PAS) is complete. As of October 3, 2014, the ABLATE PAS enrolled 3... 
Printer Friendly Version
10/03/14AtriCure to Announce Third Quarter 2014 Financial Results
WEST CHESTER, Ohio, Oct. 3, 2014 (GLOBE NEWSWIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, will release its financial results for the third quarter of 2014 on Thursday, October 30, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 30, 2014 to discuss its third quarter 2014 financial results. A live webcast of the conference call will be available online fro... 
Printer Friendly Version
09/18/14AtriCure Announces the Release of the AtriClip® FLEX
Increased shaft flexibility allows a surgeon more maneuverability within a patient’s unique anatomy when excluding the left atrial appendage WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and Left Atrial Appendage Management (LAAM), today announced the introduction of the AtriClip® FLEX, a new device with a more flexible... 
Printer Friendly Version
07/29/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following th... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
10/09/14AtriCure Completes Enrollment in Post Approval Study for the Synergy™ Ablation System
This is the largest study of its kind to evaluate surgical ablation for the treatment of chronic Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced enrollment in the ABLATE Post Approval Study (PAS) is complete. As of October 3, 2014, the ABLATE PAS enrolled 3... 
Printer Friendly Version
10/03/14AtriCure to Announce Third Quarter 2014 Financial Results
WEST CHESTER, Ohio, Oct. 3, 2014 (GLOBE NEWSWIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, will release its financial results for the third quarter of 2014 on Thursday, October 30, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 30, 2014 to discuss its third quarter 2014 financial results. A live webcast of the conference call will be available online fro... 
Printer Friendly Version
09/18/14AtriCure Announces the Release of the AtriClip® FLEX
Increased shaft flexibility allows a surgeon more maneuverability within a patient’s unique anatomy when excluding the left atrial appendage WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and Left Atrial Appendage Management (LAAM), today announced the introduction of the AtriClip® FLEX, a new device with a more flexible... 
Printer Friendly Version
07/29/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following th... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
10/30/14 
4:30 p.m. ET
Q3 2014 AtriCure, Inc. Earnings Conference Call
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.